Honduras Pharmaceuticals and Healthcare Report Q4 2017
The Honduran pharmaceutical sector will continue to be viewed as an extremely unattractivemarket for multinational drugmakers over our extended forecast period. The country's underdevelopedhealthcare system, weak regulatory environment and low levels of affordability will hold back innovativemedicine sales. We expect low-cost generic medicines will continue to dominate the market as thegovernment looked to improve healthcare coverage within a limited budget.
Headline Expenditure ProjectionsPharmaceuticals: HNL10.70bn (USD467mn) in 2016 to HNL11.11bn (USD457mn) in 2017; +3.8% inlocal currency terms, and -2.1% in US dollar terms. Forecast unchanged from last quarter.Healthcare: HNL40.41bn (USD1.76bn) in 2016 to HNL43.33bn (USD1.78bn) in 2017; +7.2% in localcurrency terms, and +1.1% in US dollar terms. Forecast revised upwards from last quarter.
In August 2017, the Medical College of Honduras (CMH) held a protest against the continuedprivatisation of healthcare services in the country as well as the ongoing shortages of medicines andmedical staff.